Table 1.
Design and outcomes of the studies included in the meta-analysis
| Num. | Author/Year | Design | Intervention assignments | Participants | Outcomes | ||||
|---|---|---|---|---|---|---|---|---|---|
| Aspirin | LMWH | Sample size, n | Mean age, years (A/L) | Male% (A/L) | Time of medication | ||||
| 1 | Robert/2023 | RCTs, MC | 81 mg bid | Enoxaparin 30 mg twice daily | 12,211 | 44.5/44.7 | 62.8/61.7 | About 1 month | All cause deaths, PE, DVT, bleeding complication, wound complication, infection (follow 90-day) |
| 2 | Zou/2014 | RCTs, SC | 100 mg qd | AxaIU 4,000 U qd | 222 | 62.7/65.7 | 25.5/17.9 | 14 days | DVT, wound complications, limb swelling (follow 4-week) |
| 3 | Anderson/2013 | RCTs, MC | 81 mg qd | Dalteparin 5,000 U qd | 785 | 57.6/57.9 | 60/53.3 | 28 days/10 days | All cause deaths, PE, DVT, major bleeding, minor bleeding, wound infection (follow 90-day) |
| 4* | Jiang/2014 | RCTs, SC | 100 mg qd | 5,000 U qd | 120 | 65.1/63.8 | 8.3/6.7 | 14 days | All cause deaths, DVT, ematoma, wound complications (follow 6-week) |
| 5* | Colwell/2010 | RCTs, MC | 81 mg qd | 30 mg Bid until discharge and then 40 mg qd | 392 | 63/62 | 45/46 | 10 days | DVT; hematoma (follow 12-week) |
| 6* | Gelfer/2006 | RCTs, SC | 100 mg qd | Enoxaparin 40 mg qd | 121 | 68/67 | 34/38 | In-hospital | All cause deaths, PE, DVT, wound drainage (follow 3-month) |
A/L = aspirin group/LMWH group; Bid = twice daily; DVT = deep vein thrombosis; LMWH = low molecular weight heparin; MC = multicenter; PE = pulmonary embolism; PS = prospective study; qd = Once a day; RCTs = randomized clinical trials; SC = single center; *Aspirin combined mobile compression device.